| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5453425 | JANSSEN PHARMS | Risperidone oral formulation |
Jul, 2014
(9 years ago) | |
| USRE39181 | JANSSEN PHARMS | Aqueous risperidone formulations |
Jul, 2014
(9 years ago) | |
| US5648093 | JANSSEN PHARMS | Pharmaceutical and other dosage forms |
Jul, 2014
(9 years ago) | |
|
US5453425 (Pediatric) | JANSSEN PHARMS | Risperidone oral formulation |
Jan, 2015
(9 years ago) | |
|
USRE39181 (Pediatric) | JANSSEN PHARMS | Aqueous risperidone formulations |
Jan, 2015
(9 years ago) | |
|
US5648093 (Pediatric) | JANSSEN PHARMS | Pharmaceutical and other dosage forms |
Jan, 2015
(9 years ago) | |
| US6224905 | JANSSEN PHARMS | Biconvex rapidly disintegrating dosage forms |
Jun, 2017
(6 years ago) | |
|
US6224905 (Pediatric) | JANSSEN PHARMS | Biconvex rapidly disintegrating dosage forms |
Dec, 2017
(6 years ago) | |
Risperdal is owned by Janssen Pharms.
Risperdal contains Risperidone.
Risperdal has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Risperdal are:
- US5453425
- USRE39181
- US5648093
- US5453425*PED
- USRE39181*PED
- US5648093*PED
- US6224905
- US6224905*PED
Risperdal was authorised for market use on 10 June, 1996.
Risperdal is available in solution;oral, tablet, orally disintegrating;oral dosage forms.
The generics of Risperdal are possible to be released after 10 December, 2017.
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 10 June, 1996
Treatment: NA
Dosage: SOLUTION;ORAL; TABLET, ORALLY DISINTEGRATING;ORAL
How can I launch a generic of RISPERDAL before it's drug patent expiration?
More Information on Dosage
RISPERDAL family patents
